Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) will likely be announcing its earnings results before the market opens ...

Tonix Pharmaceuticals shares are trading higher by 22.5% during Monday's session. The company announced that the FDA will not ...

On March 24, 2025, Tonix Pharmaceuticals Corp. (NASDAQ:TNXP) announced that the FDA will not require an Advisory Committee (AdCom) meeting regarding the New Drug Application (NDA) for TNX-102 SL ...

Investment analysts at Zacks Small Cap issued their FY2027 earnings per share (EPS) estimates for shares of Tonix Pharmaceuticals in a report issued on Thursday, April 3rd. Zacks Small Cap analyst D.

FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 11.27%, which has investors questioning if this is right time to buy.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

On March 24, Tonix Pharmaceuticals Holding announced that the FDA will not require an Advisory Committee meeting for its New ...